Weight loss drug contender Zealand Pharma jumps 17% on trial results
What are the main findings from Zealand Pharma's early-stage study on petrelintide?
Zealand Pharma's early-stage study on petrelintide showed that a high dose of the drug helped reduce weight by an average of 8.6% after 16 weekly doses. The long-acting amylin analog was judged to be safe and well-tolerated at all dose levels, with one out of 48 participants withdrawing due to negative effects5. The results support petrelintide's potential as an alternative to GLP-1 receptor agonist-based therapies for weight management.
How did petrelintide's weight loss results compare to a placebo in the study?
Petrelintide's weight loss results showed an average reduction of 8.6% in body weight after 16 weekly high doses, while the placebo group experienced a 1.7% decrease in body weight. The study involved 48 participants and demonstrated that petrelintide was well-tolerated with no serious adverse events reported.
How has the popularity of Novo Nordisk's Ozempic influenced the pharmaceutical market?
The popularity of Novo Nordisk's Ozempic has significantly impacted the pharmaceutical market, propelling the company to become Europe's most valuable firm. The demand for Ozempic and obesity drug Wegovy has intensified the race for rival treatments, attracting numerous challengers. The success of Ozempic, which contains the active ingredient semaglutide, has also driven interest in GLP-1 receptor agonist-based therapies for weight management.